Table 1—

Description of studies included in the meta-analysis

First author [ref.]CountrySample size#Specimen typeGenoType assay versionStudy designSampling methodBlinding statusSensitivity (95% CI)Specificity (95% CI)
Bang 16
 RifampicinDenmark39/88ClinicalMTBDRCross sectionalConvenienceYes100 (69–100)100 (88–100)
 IsoniazidDenmark49/88ClinicalMTBDRCross sectionalConvenienceYes85 (62–97)100 (88–100)
Barnard 17
 RifampicinSouth Africa470/936ClinicalMTBDRplusCross sectionalConsecutiveYes99 (94–100)99 (98–100)
 IsoniazidSouth Africa466/936ClinicalMTBDRplusCross sectionalRandomYes89 (83–94)100 (98–100)
Hillemann 20
 RifampicinGermany143/286IsolateMTBDRCase–controlRandomNo99 (95–100)100 (91–100)
IsoniazidGermany143/286IsolateMTBDRCase–controlRandomNo88 (81–94)100 (91–100)
Hillemann 18
 RifampicinGermany, Azerbaijan and Uzbekistan42/84ClinicalMTBDRCross sectionalConvenienceNot reported100 (78–100)100 (87–100)
IsoniazidGermany, Azerbaijan and Uzbekistan42/84ClinicalMTBDRCross sectionalConvenienceNot reported100 (80–100)100 (86–100)
Hillemann+ 19
 RifampicinGermany142/284ClinicalBothBothRandomNo97 (83–100)95 (83–99)
IsoniazidGermany142/284ClinicalBothBothConvenienceNo88 (74–96), 90 (77–97)§100 (88–100)
Hillemann+ 19
 RifampicinGermany250/500IsolateBothBothRandomNo99 (93–100)100 (93,100)
IsoniazidGermany250/500IsolateBothBothConvenienceNo88 (78–94), 92 (83–97)§100 (93–100)
Makinen 21
 RifampicinFinland52/104IsolateMTBDRCross sectionalConvenienceNot reported96 (82–100)100 (86–100)
IsoniazidRussia52/104IsolateMTBDRCross sectionalConvenienceNot reported84 (67–95)100 (83–100)
Miotto 23
 RifampicinItaly36/72ClinicalMTBDRCross sectionalConvenienceNo100 (16–100)100 (90–100)
IsoniazidItaly36/72ClinicalMTBDRCross sectionalConvenienceNo100 (54–100)100 (88,100)
Miotto 23
 RifampicinItaly206/412IsolateMTBDRCross sectionalConvenienceNo94 (88–97)95 (87–99)
IsoniazidItaly206/412IsolateMTBDRCross sectionalConvenienceNo67 (60–74)100 (89–100)
Miotto 22
 RifampicinItaly63/126ClinicalMTBDRCross sectionalConvenienceNo100 (29–100)98 (91–100)
IsoniazidItaly63/126ClinicalMTBDRCross sectionalConvenienceNo60 (26–88)92 (82–98)
Miotto 22
 RifampicinItaly69/138ClinicalMTBDRplusCross sectionalConvenienceNo100 (29–100)98 (92–100)
IsoniazidItaly69/138ClinicalMTBDRplusCross sectionalConvenienceNo73 (39–94)93 (83–99)
Somoskovi 24
 RifampicinUSA130/265ClinicalMTBDRCross sectionalConvenienceNot reported100 (86–100)97 (92–99)
IsoniazidUSA135/265ClinicalMTBDRCross sectionalConvenienceNot reported57 (46–67)100 (92–100)
Weizenegger 15
IsoniazidGermany54/108ClinicalMTBDRplusNot reportedNot reportedNot reported100 (29–100)98 (90–100)
  • CI: confidence interval. #: number analysed/total number; : data did not match with sample size reported in the study due to presence of contaminated or indeterminate results and/or the absence of drug-susceptability testing results; +: data from both versions of the GenoType MTBDR assay (Hain LifeScience GmbH, Nehren, Germany) were added together to obtain the sample size; §: for MTBDR and MTBDRplus, respectively.